Across TCGA pan-cancer cohorts, ATG4C Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATG4C data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ATG4C Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ATG4C expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC, DLBC, and LAML are the cancer types where ATG4C Mutation most reproducibly stratifies survival.